Search
Filter Results
- Resource Type
- Article1
- Article Type
- Clinical Trial1
- Clinical Study1
- English Abstract1
- Result From
- PubMed1
-
Year
- Journal Title
- Med Klin1
Search Results
- ArticleJankowski RP, Vahrson H.Med Klin. 1977 Dec 09;72(49):2122-6.19 patients with advanced ovarian cancer (FIGO-stages IIb-IV) were treated by ultra-high doses of VM26 partly according to positive oncobiograms during Multiple-drug-stoss-therapy. The toxic reactions and the cytostatic effect were investigated. The range of 57,9% remissions and the moderate toxicity suggest a specific application of VM26 in advanced ovarian cancer.